Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May;44(6):1011-1012.
doi: 10.1038/s41386-019-0336-5. Epub 2019 Feb 9.

Testing the 10 most wanted: a preclinical algorithm to screen candidate opioid use disorder medications

Matthew L Banks  1 , E Andrew Townsend  2 , S Stevens Negus  3
Affiliations
Review

Testing the 10 most wanted: a preclinical algorithm to screen candidate opioid use disorder medications

Matthew L Banks et al. Neuropsychopharmacology. 2019 May.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Proposed preclinical algorithm to evaluate candidate medications for opioid use disorder treatment. The initial decision in the medication development process is to determine whether the candidate medication is directed towards non-dependent individuals (Track#1) or opioid-dependent individuals (Track#2). For each Track, compounds would be evaluated through a series of steps that are initially sensitive (e.g., Steps #1 and 2: are decreases in opioid self-administration observed after acute treatment and sustained or emergent following repeated treatment?) and become progressively more selective (e.g., Step #4: does repeated treatment decrease opioid choice and produce a reciprocal increase in non-drug alternative choice?). Candidate medications that are effective through all four steps would have the highest priority for promotion to clinical evaluation, whereas candidate medications that fail along the track would have progressively lower priority the earlier in the Track that the failure occurred. Fixed-ratio (FR); Progressive-ratio (PR); Withdrawal (WD)
See this image and copyright information in PMC

References

    1. Rasmussen Kurt, White David A., Acri Jane B. NIDA’s medication development priorities in response to the Opioid Crisis: ten most wanted. Neuropsychopharmacology. 2018;44(4):657–659. doi: 10.1038/s41386-018-0292-5. - DOI - PMC - PubMed
    1. Mello NK, Negus SS. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology. 1996;14:375–24. doi: 10.1016/0893-133X(95)00274-H. - DOI - PubMed
    1. Negus SS, Banks ML. Medications development for opioid abuse. Cold Spring Harb Perspect Med. 2013;3:a012104. doi: 10.1101/cshperspect.a012104. - DOI - PMC - PubMed
    1. Banks ML, Negus SS. Insights from preclinical choice models on treating drug addiction. Trends Pharmacol Sci. 2017;38:181–94. doi: 10.1016/j.tips.2016.11.002. - DOI - PMC - PubMed
    1. Czoty PW, Stoops WW, Rush CR. Evaluation of the "pipeline" for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research. Pharmacol Rev. 2016;68:533–62. doi: 10.1124/pr.115.011668. - DOI - PMC - PubMed

Publication types